Invention Grant
- Patent Title: Fused imidazole derivatives as IL-17 modulators
-
Application No.: US16959339Application Date: 2019-01-10
-
Publication No.: US11472794B2Publication Date: 2022-10-18
- Inventor: Gareth Neil Brace , Rose Elizabeth Bardell-Cox , Gregory Foulkes , James Richard Frost , Helen Tracey Horsley , Elizabeth Pearl Jones , Fabien Claude Lecomte , James Thomas Reuberson , Monika-Sarah Elizabeth Dorothea Schulze , Richard David Taylor , Wei Tsung Yau , Zhaoning Zhu
- Applicant: UCB Biopharma SRL
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SRL
- Current Assignee: UCB Biopharma SRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB1800639.5 20180115,GB1820172.3 20181211
- International Application: PCT/EP2019/050594 WO 20190110
- International Announcement: WO2019/138017 WO 20190718
- Main IPC: C07D403/12
- IPC: C07D403/12 ; C07D413/12 ; C07D407/14 ; C07D235/16 ; C07D401/14 ; C07D413/14
Abstract:
A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
Public/Granted literature
- US20210053952A1 Fused Imidazole Derivatives as IL-17 Modulators Public/Granted day:2021-02-25
Information query
